Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A [(3R,5R)-7-[3-phenyl-4-[(phenylcarbamoyl]-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt (2:1)], medicinal preparations containing the new polymorph form, process for the preparation thereof and the use of the new polymorph form for the preparation of medicinal products .
UAA200712404A2005-04-082006-04-07Crystalline atorvastatin hemicalcium salt polymorph form
UA93202C2
(en)
Pharmaceutical preparation containing atorvastatin calcium salt, process for the production of this preparation and its use for the treatment of hypercholesterolemia and hyperlipidemia
Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
Crystalline form iii (r-(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1h-heptanoic acid hemi calcium salt (atorvastatin) and pharmaceutical compositions containing it
Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
IMPROVED PROCESS FOR THE PREPARATION OF [3R,5R]-2-FLUOROPHENYL-β,δ- DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(2-HYDROXYPHENYLAMINO)- CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID, SODIUM SALT
Process of preparing a pharmaceutical composition comprising obtaining the hemic acid salt of the acid [r- (r *, r *)] - 2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3 -phenyl-4 - [(phenylamino) carbonyl] -1h-pyrrole-1-heptanoic acid and add a pharmaceutically acceptable carrier to said compound (divisional of application 1301-03).